Salah-Eldin, M A <br/><br/>
Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a Phase II study.  [electronic resource] 

 -  Indian journal of cancer   
 - 169-75 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1998-4774 
<br/><br/><label>Standard No.: </label>10.4103/0019-509X.98944  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bridged-Ring Compounds--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Humans<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Ovarian Neoplasms--drug therapy<br/>Oxaliplatin<br/>Survival Analysis<br/>Taxoids--administration & dosage